Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann, Jonathan A
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. [electronic resource] - The Lancet. Oncology Nov 2016 - 1579-1589 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
1474-5488
10.1016/S1470-2045(16)30376-X doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
BRCA1 Protein--genetics
BRCA2 Protein--genetics
Cystadenocarcinoma, Serous--drug therapy
Double-Blind Method
Female
Humans
Middle Aged
Mutation
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Phthalazines--adverse effects
Piperazines--adverse effects
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. [electronic resource] - The Lancet. Oncology Nov 2016 - 1579-1589 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
1474-5488
10.1016/S1470-2045(16)30376-X doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
BRCA1 Protein--genetics
BRCA2 Protein--genetics
Cystadenocarcinoma, Serous--drug therapy
Double-Blind Method
Female
Humans
Middle Aged
Mutation
Neoplasm Recurrence, Local--drug therapy
Ovarian Neoplasms--drug therapy
Phthalazines--adverse effects
Piperazines--adverse effects
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use